Russian Northern Fleet completes drills in ArcticMilitary & Defense September 22, 18:01
OPEC and non-OPEC countries to continue talks on oil production cut dealBusiness & Economy September 22, 17:28
Russian pair figure skaters Kavaguti, Smirnov retire from sportSport September 22, 16:48
Record number of delegations register for St. Petersburg-hosted IPU AssemblyRussian Politics & Diplomacy September 22, 16:47
Astronauts to make quickest trip ever to ISS in DecemberScience & Space September 22, 16:27
Russian frigate Admiral Essen returns to Crimea after mission in MediterraneanMilitary & Defense September 22, 16:24
Experts believe Russia not ready for crypto assetsBusiness & Economy September 22, 16:09
Trump vows to put North Korean leader to testWorld September 22, 15:56
Russia's top diplomat presents UN chief with film about him made by TASSSociety & Culture September 22, 15:43
SINGAPORE, July 3, 2013 /PRNewswire/ -- NeuroAiD, a stroke treatment based on Traditional Medicine, increases the odds of achieving a better functional outcome, according to research published online in the journal Stroke.
The CHIMES study is an academic international double-blind placebo-controlled clinical trial which included 1100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, treated and monitored for 3 months. Researchers found that patients who were taking NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence in function and being able to perform daily activities at the end of three months. This effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.
The odds ratio was the highest among recently completed stroke trials of neuroprotective agents. The benefit observed is clinically relevant and might have reached statistical significance with a larger sample size. In addition the study confirmed the excellent safety profile of NeuroAiD. Stroke survivors who were on NeuroAiD had fewer adverse events than those in the control group. Further studies will likely look into the benefits of longer duration of treatment.
Prof Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study, said the results looked very promising and suggested that the effectiveness of such herbal supplements could have a great impact on stroke management. "I think one thing which is very clear is that NeuroAiD is safe in acute stroke. A previous meta-analysis suggested that NeuroAiD is efficacious and safe in the chronic stage of stroke. Now the Chimes study has provided us with much more reliable data about the safety and efficacy of NeuroAiD in acute stroke. I think the CHIMES results are not only a step forward, but also a major achievement."
Each year, 20 million people suffer from the devastating disease. However, there are only a few effective, generally accepted and specific treatments available. Therefore, there is an increasing need for multi-modal therapies to help more patients recover quickly and effectively from stroke. Moleac, a Singapore based bio-pharma company, developed NeuroAiD to meet this need.